In the meta-regression analysis , changes in plasma cortisol concentrations following statin therapy were found to be independent of treatment duration .
Results of this meta- analysis of RCTs suggest a significant elevation in plasma cortisol levels following statin therapy
This study aim ed to perform a systematic review and meta- analysis of r and omized controlled trials ( RCTs ) in order to calculate the effect size of statin therapy in changing plasma cortisol concentrations .
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.
CONTEXT Heterozygous familial hypercholesterolemia ( HeFH ) is a common disorder associated with early coronary artery disease , especially in men . The age at which drug therapy should be started is still controversial , as is the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ( statins ) . OBJECTIVE To assess the lipid-lowering efficacy , biochemical safety , and effect on growth and sexual development of lovastatin in adolescent boys with HeFH . DESIGN One-year , double-blind , placebo-controlled , balanced , 2-period , 2-arm r and omized trial . In the first period ( 24 weeks ) , lovastatin was increased at 8 and 16 weeks and the dosage remained stable during the second period ( 24 weeks ) . The study was conducted between 1990 and 1994 . SETTING Fourteen pediatric outpatient clinics in the United States and Finl and . PATIENTS Boys aged 10 to 17 years with HeFH . Of 132 r and omized subjects ( 67 intervention , 65 placebo ) , 122 ( 63 intervention , 59 placebo ) and 110 ( 61 intervention , 49 placebo ) completed the first and second periods , respectively . INTERVENTION Lovastatin , starting at 10 mg/d , with a forced titration at 8 and 16 weeks to 20 and 40 mg/d , respectively , or placebo . MAIN OUTCOME MEASURES The primary efficacy outcome measure was low-density lipoprotein cholesterol ( LDL-C ) . Primary safety measures were growth and sexual development . RESULTS Compared with placebo , LDL-C levels of patients receiving lovastatin decreased significantly ( P<.001 ) by 17 % , 24 % , and 27 % receiving dosages of 10 , 20 , and 40 mg/d , respectively , and remained 25 % lower than baseline at 48 weeks . Growth and sexual maturation assessed by Tanner staging and testicular volume were not significantly different between the lovastatin and placebo groups at 24 weeks ( P = .85 ) and 48 weeks ( P = .33 ) ; neither were serum hormone levels or biochemical parameters of nutrition . However , the study was underpowered to detect significant differences in safety parameters . Serum vitamin E levels were reduced with lovastatin treatment consistent with reductions in LDL-C , the major carrier of vitamin E in the circulation . CONCLUSIONS This study in adolescent boys with HeFH confirmed the LDL-C-reducing effectiveness of lovastatin . Comprehensive clinical and biochemical data on growth , hormonal , and nutritional status indicated no significant differences between lovastatin and placebo over 48 weeks , although further study is required
In the meta-regression analysis , changes in plasma cortisol concentrations following statin therapy were found to be independent of treatment duration .
Results of this meta- analysis of RCTs suggest a significant elevation in plasma cortisol levels following statin therapy
This study aim ed to perform a systematic review and meta- analysis of r and omized controlled trials ( RCTs ) in order to calculate the effect size of statin therapy in changing plasma cortisol concentrations .